Condition: Glioblastoma · Malignant Glioma · Recurrent Glioblastoma · Sponsor: Marcela V. Maus, M.D.,Ph.D.
The goal of this research study is to determine the best dose of CARv3-TEAM-E T Cells for treating participants with glioblastoma. The name of the treatment intervention used in this research study is: -CARv3-TEAM-E T Cells (or Autologous T lymphocytes).
This description comes directly from the study's public registry record.
William Curry, MD · 617-724-6226 · carteamingbm@mgb.org
Always discuss trial participation with your own doctor first.
| Massachusetts General Hospital Cancer Center | Boston, Massachusetts, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05660369